SCHEMBL547775

SCHEMBL547775

C[C@H]1[C@H](C)CC[C@]2(C(=O)O)CC[C@]3(C(=O)O)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)C5CC[C@]43C)[C@H]12

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.84
SENP1 Q9P0U3 3/20 0.84
POLB P06746 3/20 0.84
HSD11B1 P28845 3/20 0.84
MEN1 O00255 2/20 0.84
KMT2A Q03164 2/20 0.84
PTPN2 P17706 2/20 0.84
PTPN6 P29350 2/20 0.84
GPBAR1 Q8TDU6 2/20 0.84
USP7 Q93009 2/20 0.84
RECQL P46063 2/20 0.84
AKR1B10 O60218 1/20 0.84
CTSD P07339 1/20 0.84
PTPRF P10586 1/20 0.84
CYP19A1 P11511 1/20 0.84
CETP P11597 1/20 0.84
AKR1B1 P15121 1/20 0.84
CES1 P23141 1/20 0.84
ACP1 P24666 1/20 0.84
EPHX2 P34913 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL547774 1.00 PTPN1 (0.84) PTPN1SENP1POLBHSD11B1MEN1
Ursolic Acid SCHEMBL14132123 0.91 PTPN1 (1.00) PTPN1SENP1POLBHSD11B1MEN1
Ursolic Acid SCHEMBL13395361 0.91 PTPN1 (1.00) PTPN1SENP1POLBHSD11B1MEN1
Ursolic Acid SCHEMBL18428537 0.91 PTPN1 (1.00) PTPN1SENP1POLBHSD11B1MEN1
Ursolic Acid SCHEMBL12300180 0.91 PTPN1 (1.00) PTPN1SENP1POLBHSD11B1MEN1
Ursolic Acid SCHEMBL23314191 0.91 PTPN1 (1.00) PTPN1SENP1POLBHSD11B1MEN1
Ursolic Acid SCHEMBL16994210 0.91 PTPN1 (1.00) PTPN1SENP1POLBHSD11B1MEN1
Ursolic Acid SCHEMBL19714770 0.91 PTPN1 (1.00) PTPN1SENP1POLBHSD11B1MEN1
Ursolic Acid SCHEMBL21819718 0.91 PTPN1 (1.00) PTPN1SENP1POLBHSD11B1MEN1
Ursolic Acid SCHEMBL5713287 0.91 PTPN1 (1.00) PTPN1SENP1POLBHSD11B1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240245744-A1 INTRANASAL ADMINSTRATION OF CANNABIGEROL, CBDa, CBGa, & UNCARIA TOMENTOSA HYDROALCOHOLIC EXTRACT COMPOUNDS EMULSIFIED IN SALINE HOMOGENOUS SOLUTION FOR INTRANASAL ADMINISTRATION CLARK ARTIS ASAHEL (US) 2024-07-25 US claimed
CN-107115568-A Self assembly lysozyme multilayer membrane preparation method with antibiotic property and biocompatibility 温州生物材料与工程研究所 2017-09-01 CN claimed
CN-106798947-A A kind of self-assembled protein multilayer membrane preparation method 温州生物材料与工程研究所 2017-06-06 CN claimed
US-20100227827-A1 METHOD OF INCREASING TRYPTOPHAN AND NICOTINAMIDE LEVELS IN VIVO GENETIC HEALTH ENTERPRISES (PTY) LTD. (ZA) 2010-09-09 US claimed
US-20080206162-A1 Composition and Methods for Treating Alzheimer's Disease and Other Amyloidoses UNIVERSITY OF WASHINGTON 2008-08-28 US claimed
WO-2008008837-A2 A METHOD OF INCREASING TRYPTOPHAN AND NICOTINAMIDE LEVELS IN VIVO LYNPETE TRADING 6 (PTY) LTD. TRADING AS GENETIC HEALTH ENTERPRISES (ZA) 2008-01-17 WO claimed
EP-1019044-B1 COMPOSITION AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES UNIV WASHINGTON (US) 2007-04-11 EP claimed
US-20040086585-A1 Composition and methods for treating Alzheimer's disease and other amyloidoses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-05-06 US claimed
US-20040076698-A1 Composition and methods for treating Alzheimer's disease and other amyloidoses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-04-22 US claimed
EP-1019044-A4 COMPOSITION AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES UNIV WASHINGTON (US) 2004-01-07 EP claimed
US-20010055630-A1 Compostion and methods for treating alzheimer's disease and other amyloidoses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2001-12-27 US claimed
EP-1019044-A1 COMPOSITION AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES University of Washington (US) 2000-07-19 EP claimed
WO-1998051302-A1 COMPOSITION AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES UNIVERSITY OF WASHINGTON (US) 1998-11-19 WO claimed
US-4606911-A PENTACYCLIC ACID TRITERPENES ROHTO PHARMACEUTICAL CO. LTD. (JP) 1986-08-19 US claimed
US-20240100113-A1 TERPENE-CONTAINING COMPOSITIONS QSI HOLDING COMPANY INC (US) 2024-03-28 US disclosed
WO-2022124583-A1 COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES, COMPRISING QUINOVIC ACID 경상국립대학교 산학협력단 2022-06-16 WO disclosed
US-20210346453-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF COVID-19 COGNITIVE CLARITY INC. (US) 2021-11-11 US disclosed
US-5648449-A Copolyesters, molded articles from the same and aromatic triols used for producing the same KURARAY CO., LTD. (JP) 1997-07-15 US disclosed
EP-0725051-A2 Copolyesters, molded articles from the same and aromatic triols used for producing the same KURARAY CO., LTD. (JP) 1996-08-07 EP disclosed
US-4606911-A PENTACYCLIC ACID TRITERPENES ROHTO PHARMACEUTICAL CO. LTD. (JP) 1986-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227827-A1 METHOD OF INCREASING TRYPTOPHAN AND NICOTINAMIDE LEVELS IN VIVO NNMT, AADAT, AANAT PTPN1 4034/4885SENP1 2330/4885POLB 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.